PTC Therapeutics Inc [NASDAQ: PTCT] traded at a low on Tuesday, posting a -10.97 loss after which it closed the day’ session at $36.19.
The results of the trading session contributed to over 4179879 shares changing hands. Over the past one week, the price volatility of PTC Therapeutics Inc stands at 6.43% while the volatility over the past one month is 7.13%.
The market cap for PTCT stock reached $2.85 billion, with 77.70 million shares outstanding and 76.82 million shares in the current float. Compared to the average trading volume of 1.02M shares, PTCT reached a trading volume of 4179879 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about PTC Therapeutics Inc [PTCT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PTCT shares is $62.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PTCT stock is a recommendation set at 2.27. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for PTC Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 11, 2025. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Perform. The new note on the price target was released on March 07, 2025, representing the official price target for PTC Therapeutics Inc stock. Previously, the target price had yet another raise from $45 to $67, while Morgan Stanley kept a Overweight rating on PTCT stock. On December 03, 2024, analysts increased their price target for PTCT shares from 39 to 63.
The Average True Range (ATR) for PTC Therapeutics Inc is set at 3.27, with the Price to Sales ratio for PTCT stock in the period of the last 12 months amounting to 3.54.
How has PTCT stock performed recently?
PTC Therapeutics Inc [PTCT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.92. With this latest performance, PTCT shares dropped by -16.30% in over the last four-week period, additionally sinking by -9.34% over the last 6 months – not to mention a rise of 7.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PTCT stock in for the last two-week period is set at 26.28, with the RSI for the last a single of trading hit 18.77, and the three-weeks RSI is set at 31.34 for PTC Therapeutics Inc [PTCT]. The present Moving Average for the last 50 days of trading for this stock 49.95, while it was recorded at 45.23 for the last single week of trading, and 43.03 for the last 200 days.
PTC Therapeutics Inc [PTCT]: Deeper insight into the fundamentals
PTC Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.31 and a Current Ratio set at 2.35.
Insider trade positions for PTC Therapeutics Inc [PTCT]
The top three institutional holders of PTCT stocks are: VANGUARD GROUP INC with ownership of 8.97 million shares, which is approximately 11.696%. WELLINGTON MANAGEMENT GROUP LLP, holding 8.21 million shares of the stock with an approximate value of $$251.02 million in PTCT stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$237.67 million in PTCT stock with ownership which is approximately 10.1299%.
